Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P McGovern

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
BMC Medicine|April 14, 2019
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND studyAndrew P McGovern, John M Dennis, Beverley M Shields, et al.
Primary Care Diabetes|May 31, 2018
Type 2 diabetes: A protective factor for COPD?Louise H Rayner, Andrew P McGovern, Julian Sherlock, et al.
Diabetes, Obesity & Metabolism|October 14, 2022
Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studiesWilliam Hinton, Abdus Samad Ansari, Martin B Whyte, et al.
Wellcome Open Research|October 10, 2025
Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataLaura M Güdemann, John M Dennis, Andrew P McGovern, et al.
Plos One|August 26, 2016
Physician Associate and General Practitioner Consultations: A Comparative Observational Video StudySimon de Lusignan, Andrew P McGovern, Mohammad Aumran Tahir, et al.
Diabetes, Obesity & Metabolism|April 21, 2026
Higher Body Mass Index Is a Causal Risk Factor for Skin Infections: A Mendelian Randomisation Study Using UK Biobank and FinnGenRhian Hopkins, Ethan de Villiers, Michael N Weedon, et al.
Clinical Therapeutics|February 14, 2021
Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRDRuth E Farmer, Ivan Beard, Syed I Raza, et al.
Diabetes, Obesity & Metabolism|January 6, 2025
Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort studyRhian Hopkins, Katherine G Young, Nicholas J Thomas, et al.
Diabetologia|May 22, 2023
Correction to: The impact of population-level HbA<sub>1c</sub> screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysisKatherine G Young, Andrew P McGovern, Inês Barroso, et al.
Diabetologia|November 21, 2022
The impact of population-level HbA<sub>1c</sub> screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysisKatherine G Young, Andrew P McGovern, Inês Barroso, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
BMC Medicine|April 14, 2019
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND studyAndrew P McGovern, John M Dennis, Beverley M Shields, et al.
Primary Care Diabetes|May 31, 2018
Type 2 diabetes: A protective factor for COPD?Louise H Rayner, Andrew P McGovern, Julian Sherlock, et al.
Diabetes, Obesity & Metabolism|October 14, 2022
Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studiesWilliam Hinton, Abdus Samad Ansari, Martin B Whyte, et al.
Wellcome Open Research|October 10, 2025
Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataLaura M Güdemann, John M Dennis, Andrew P McGovern, et al.
Plos One|August 26, 2016
Physician Associate and General Practitioner Consultations: A Comparative Observational Video StudySimon de Lusignan, Andrew P McGovern, Mohammad Aumran Tahir, et al.
Diabetes, Obesity & Metabolism|April 21, 2026
Higher Body Mass Index Is a Causal Risk Factor for Skin Infections: A Mendelian Randomisation Study Using UK Biobank and FinnGenRhian Hopkins, Ethan de Villiers, Michael N Weedon, et al.
Clinical Therapeutics|February 14, 2021
Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRDRuth E Farmer, Ivan Beard, Syed I Raza, et al.
Diabetes, Obesity & Metabolism|January 6, 2025
Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort studyRhian Hopkins, Katherine G Young, Nicholas J Thomas, et al.
Diabetologia|May 22, 2023
Correction to: The impact of population-level HbA<sub>1c</sub> screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysisKatherine G Young, Andrew P McGovern, Inês Barroso, et al.
Diabetologia|November 21, 2022
The impact of population-level HbA<sub>1c</sub> screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysisKatherine G Young, Andrew P McGovern, Inês Barroso, et al.
Pageof 4